
|Articles|November 2, 2006
Injectable enzyme appears effective in treating Peyronie's disease
An investigational injectable enzyme known as AA4500 appears to be effective and generally well tolerated in treating patients with Peyronie's disease, according to data from two phase II open-label trials presented at the recent AUA Western Section annual meeting in Maui, HI.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
NDV-01 produces robust 9-month results in high-risk NMIBC
2
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
3
SUO 2025 data confirm IsoPSA accuracy independent of mpMRI use
4
SYNC-T demonstrates high bone metastasis resolution in phase 1 cohort
5

















